Hologic initiated with a Hold at Jefferies

Jefferies initiated coverage of Hologic (HOLX) with a Hold rating and $85 price target The firm says that while the company is “better capitalized than ever,” the strength of its new business portfolio is unclear as sales continue to underperform peers. Hologic has “noisiness” around its 2025 guide and lingering overhangs that further complicate the nearer-term story, the analyst tells investors in a research note.